In vivo phosphorus magnetic resonance spectroscopy in multiple sclerosis.

Area of Science:

• Neuroimaging
• Biochemistry
• Neurology

Background:

• Multiple Sclerosis (MS) is a chronic neurological disease affecting the central nervous system.
• Understanding the metabolic changes in MS is crucial for assessing disease progression and severity.

Purpose of the Study:

• To investigate brain metabolite alterations in multiple sclerosis (MS) patients using phosphorus magnetic resonance spectroscopy (31P-MRS).
• To correlate metabolic changes with clinical disability and disease course in MS.

Main Methods:

• Localized 31P-MRS was conducted at 1.5 Tesla on 39 MS patients and 15 healthy controls.
• Spectra were analyzed for levels of creatine phosphate (CrP), phosphomonoesters (PME), phosphodiesters (PDE), inorganic phosphate (Pi), and beta-adenosine triphosphate (beta-ATP).
• Metabolite levels were correlated with the Expanded Disability Status Scale (EDSS) and MS disease type (relapsing-remitting vs. progressive).

Main Results:

• MS patients exhibited significantly increased creatine phosphate (CrP) levels compared to controls.
• Elevated CrP levels were positively correlated with the severity of neurological handicap (EDSS).
• CrP increases were more pronounced in patients with a progressive disease course than in those with relapsing-remitting MS.
• No significant abnormalities were detected in PME, PDE, Pi, beta-ATP levels, or brain pH values in MS patients.

Conclusions:

• Increased brain creatine phosphate levels in MS suggest a reduced metabolic state.
• CrP levels serve as a potential biomarker for disease severity and progression in multiple sclerosis.
• 31P-MRS can detect metabolic alterations associated with the pathophysiology of MS.